INTRODUCTION
Since the mid-1800's considerable interest has centered on the role of the central and autonomic nervous systems in modifying glucose homeostasis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Pertinent to this study is the evidence that has accumulated in support of a role for the autonomic nervous system in modifying insulin release from the pancreas. This has included the demonstration that epinephrine can inhibit Dr. Burr is an Investigator of the Howard Hughes Medical Institute.
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insulin release in vitro (11, 12) and in vivo (13, 14) , an effect ascribed to a-adrenergic receptor activation (12, 15, 16) , possibly mediated through modification in calcium flux (15) . In contrast to the a-adrenergic effect, a stimulatory effect of 13-adrenergic agents on insulin release has been demonstrated (12, 17, 18) . Further, prior exposure of pancreatic pieces to the adrenergic agents epinephrine, norepinephrine (12) , and diazoxide (19) has resulted in enhancement of the insulin response to subsequent glucose challenge, an effect apparently dependent on the integrity of both a-and 3-adrenergic receptors. Data have also accumulated to support a role for the parasympathetic autonomic nervous system in modifying insulin release. Acetylcholine stimulates insulin release in vitro (11, 15) , as defined in a static system, and cholinergic agents (20, 21) including nicotinic acid (22) stimulate insulin release in vivo. Further, both vagal stimulation (23, 24) and pancreatic nerve stimulation (25) result in an increase in insulin release. Finally, atropinie has been showIn to inhlibit conditioned insulin release (26) , insulin release secondary to vagal stimulation (20, 21) , and to inhibit insulin release in response to oral glucose but not that induced by intravenous glucose (27) .
This study was designed to determine the effects of cholinergic agents on the two phases of glucose-induced insulin release as defined in an in vitro dynamic system, to define any dose dependency of these effects, and to determine the effect of the glucose concentration on these responses.
METHODS
This study utilized a modification of the perifusion system previously described (12, 19, 28, 29) . In the present system pancreatic islets were used in lieu of pancreatic pieces: although this is more complicated, some advantages have accrued. First, the basal insulin release is reduced. Second, the requirement for Trasylol in the system is obviated. And third, the reproducibility appears to be enhanced. Islets were obtained by a modification of the methods of Lacy Buffer flow through the chambers was maintained at 2.0-2.2 ml/min by means of a double-channel continuous infusion pump. Buffers and perifusion chambers were kept at 37°C by means of a closed water jacket system under thermostatic control. Buffers were continuously gassed with 95% 02, and 5%o C02, and the pH was maintained at 7.4. The KRB buffer used contained 0.5 g/100 ml bovine serum albumin.
In each of these experiments, a prestimulation period of 25 min perifusion with KRB plus glucose, 50 mg/100 ml preceded the experimental periods of 60 min. The anatomical integrity of the islets after 2 h perifusion was confirmed by electron microscopy, and physiological responsiveness remained intact for up to 4 h of perifusion.
Effluent samples were collected continuously with a fraction collector mounted in a cold box. X 10-' mM, also in the presence and absence of glucose, and (d) nicotinic acid (2.7 x 10-5.4 x 10-mM), similarly in the presence and absence of glucose. Finally, the effect of atropine, .1.1 X 10' mM, was determined on insulin released by 16.4 mM glucose and on insulin release induced by AcCh, 1.1 X 10-' mM, plus 2.4 mM glucose. In these experiments control and test experiments were run in parallel, where appropriate.
The first and second phases of the biphasic responses were defined by dynamic studies and the total amounts of insulin released during these phases were calculated by simple addition for the first phase (over which all samples were assayed) and by assessment of the area under the insulin release rate: time plot for the second phase (not all samples were assayed-all for the first 5 min, then every fifth sample to 60 min). This method provides an accurate assessment of the total amount of insulin released in the second phase, as confirmed in this and in previous studies, by measuring the insulin content of all the perifusate collected over the appropriate period (12, 19) . For those studies that exhibited flat responses, phases were arbitrarily defined by reference to appropriate matching experiments (12, 19) . Statistics used either the Wilcoxon rank test and/or the Student t test. Table I , in the absence of glucose, none of the agents used (in concentrations up to 5.4 X 10' mM) produced any significant acute (first phase) insulin release above that seen with buffer alone. Further, neither MC nor nicotinic acid produced enhancement of insulin release above basal during the latter portions of the perifusion. AC, 5.5 X 10 mM, did enhance this Table II ). These effects were significant for both phases of insulin release (Table II) . Further, the effects were dose-dependent for both agents. In contrast, nicotinic acid did not affect either the first or second phase of insulin release in the presence of 2.4 mM glucose (Table II).
RESULTS

As indicated in
Comparison of the dose response curves relating log [AcCh] to total amount of insulin released during the first phase of insulin release with that relating log (AcCh) to the total amount of insulin released during the second phase of insulin release reveals lack of parallelism of the two curves, with an acute increase in responsiveness of the second phase occurring one to two orders of AcCh concentration lower than the concentration at which a similar increase in responsiveness of the first phase is observed (Fig. 3) .
In contrast to the marked effects of muscarinic agents in the presence of 2.4 mM glucose, either AcCh or MCh had much less effect when added to 16.4 mM glucose (Table III) . Thus, AcCh 2.7 X 10' mM had no effect on either the first or second phases of insulin release induced by 16.4 mM glucose, whereas 5.4 X 10' mM AcCh produced significant enhancement of only the secondary phase. Mc had minimal effect on both phases of glucose-induced insulin release. This was statistically significant for the first phase at both 2.7 X 10 and 5.4 X 104 mM, and for the second phase only at 5.4 X 10-mM. Nicotinic acid had no effect on insulin release induced by 16.4 mM glucose in concentrations up to 5.4 X 10' mM. The marked differences noted in the response to muscarinic agents due to changes in glucose concentration are illustrated by comparison of Tables I, II , and III. The increments observed in both phases of insulin release induced by both concentrations (2.7 X 10O mM and 5.4 X10' mM) of the muscarinic agents were greater in the presence of 2.4 mM glucose than those observed in either the absence of glucose or in the presence of 16.4 mM glucose (Fig. 4) Atropine, 1.1 X 10-' mM, inhibited both phases of insulin release in response to 1.1 X 10-' mM AcCh in the presence of 2.4 mM glucose and also inhibited both phases of the insulin release in response to 16.4 mM glucose (Table IV) . The insulin release in response to 1.1 X 10-' mM AcCh plus 2.4 mM glucose was comparable to that induced by 16 by cholinergic agents (11, 15 anid the effect of cholinergic antagonists on centrally in-duced insulin release (26) . That is, it is possible that reflex functions in response to food, local or central, may influence insulin release. Furthermore, the marked sensitivity of the islet to cholinergic agents, particularly the acute response, is such as would be expected if "anticipation" were necessary to elicit normal insulin responses. In this context it has been demonstrated that insulin release may be provoked both hypnotically (35) and by sham feeding (36, 37) . These observations, about acute responsiveness of the bursa-derived cell to AcCh and the apparent presence of reflex pathways, have potential significance in that there appears to be a "delay" in insulin release in diabetics (38) (39) (40) . These results may also be considered in light of previous data suggesting that while both phases of glucose induced insulin release may be influenced by similar agents, there are differences, at least in emphasis, in the major mechanisms through which these phases are generated (12, 19, 29, 41, 42) . Thus, it is observed that while muscarinic agents can stimulate biphasic insulin release in the presence of glucose, it is evident that the dose-response relationships are different for the two phases. The agents used appear to be more effective at lower concentrations in generating the second versus the first phase. Further, atropine at equimolar concentration with AcCh produced differing degrees of inhibition of the two phases of AcCh-inducd insulin release (90% inhibition of the first versus 56% inhibition of the second). In the presence of near-maximal stimulation of insulin release by glucose, neither AcCh nor MCh provided very much increment in either phase of insulin release except at very high concentrations (2.7 X 10' mM). That is, these agents were less effective insulinogogues in the presence of high glucose concentrations. This type of response may be expected if the major role of parasympathetically mediated insulin release was in the acute or reflex stage, but it is a response that would allow for further modification by parasympathetic mechanisms should the need arise.
Finally, atropine in the concentration used (equimolar with that concentration of AcCh that produces comparable insulin release to that obtained with 16.4 mM glucose) not only inhibited insulin release induced by AcCh but also inhibited glucose-induced insulin release. While atropine was less effective in inhibiting the first phase of insulin release induced by glucose than by AcCh, it was equally effective in inhibiting the secondary phases of insulin release induced by either agent. These observations raise questions regarding the specificity of the effect of atropine on B-cell function and hence on the validity of the assumption that inhibition of insulin release by atropine is solely due to inhibition of a cholinergically mediated process. Furthermore, the observations suggest that AcCh and glucose share, at least in part, a common primary pathway in initiating insulin release and/or that their stimulatory effect is dependent on a common "permissive" event that is blocked by atropine. These latter possibilities are supported by the observation that AcCh produced a lesser increment in insulin release at higher glucose concentrations than at lower glucose concentrations.
In summary. Insulin release in vitro appears to be particularly sensitive to cholinergic stimulation; the two phases of insulin release exhibit different orders of sensitivity to cholinergic agents and to the inhibitory effect of atropine; the effects of cholinergic stimulation are dependent on the glucose concentration; and that the inhibitory effects of atropine on insulin release are not limited to inhibition of cholinergic insulinogogue activity.
